MET and non-small cell lung carcinoma: In non-small cell lung cancer the results are inconsistent [38], however HGFR protein levels have been reported to be predictive for anti-MET treatment in clinical studies [39, 40, 41] whereas these results were not confirmed in a phase III trial (METLung) [42].